BioCentury | Sep 8, 2014
Analyst Picks & Changes

Analyst picks & changes

...Activating Systems), which Kolbert believes is "best in class." Kolbert said that part of his "epiphany"...
BioCentury | Nov 23, 2009
Clinical News

Valomaciclovir: Phase IIb data

...lesion formation. There were no differences in significant adverse events between treatment groups. Medivir granted Epiphany...
...in 2006 (see BioCentury, Sept 11, 2006). GlaxoSmithKline plc (LSE:GSK; NYSE:GSK, London, U.K.) markets Valtrex. Epiphany Biosciences Inc....
BioCentury | Nov 19, 2009
Clinical News

Epiphany's valomaciclovir meets Phase IIb endpoint

...complete crusting of shingles rash (p<0.007). The double-blind, North American trial (EPB348-0201) enrolled 373 patients. Epiphany...
BioCentury | Apr 9, 2009
Distillery Therapeutics

This week in therapeutics

...for the mutated protein. Valomaciclovir, a varicella zoster DNA polymerase inhibitor from Medivir AB and Epiphany Biosciences Inc....
BioCentury | Mar 5, 2009
Distillery Therapeutics

Indication: Infectious disease

...have vaccines against VZV in early-stage clinical testing. Inhibitex Inc. and partners Medivir AB and Epiphany Biosciences Inc....
BioCentury | Jan 5, 2009
Company News

Epiphany, University of Erlangen-Nuermberg deal

...detect HHV-8. Epiphany expects to launch a diagnostic this year. Financial terms were not disclosed. Epiphany Biosciences Inc....
BioCentury | Sep 22, 2008
Clinical News

Valomaciclovir: Phase IIb ongoing

...vs. 3 times daily Valtrex valacyclovir from GlaxoSmithKline plc (LSE:GSK; GSK, London, U.K.). Medivir granted Epiphany...
...valomaciclovir to treat shingles associated with varicella zoster virus infection (see BioCentury, Sept 6, 2006). Epiphany Biosciences Inc....
BioCentury | Dec 10, 2007
Clinical News

Valomaciclovir: Phase II started

...granted Epiphany worldwide rights outside the Nordic countries to valomaciclovir (see BioCentury, Sept 6, 2006). Epiphany Biosciences Inc....
BioCentury | Nov 12, 2007
Clinical News

Valomaciclovir: Phase IIb started

...once-daily valomaciclovir vs. thrice-daily Valtrex valacyclovir from GlaxoSmithKline plc (LSE:GSK; GSK, London, U.K.). Medivir granted Epiphany...
...valomaciclovir to treat shingles associated with varicella zoster virus infection (see BioCentury, Sept 6, 2006). Epiphany Biosciences Inc....
BioCentury | Sep 3, 2007
Strategy

Back to School 2007: Innovation & leadership

...Phase II to treat disease states associated with water retention. Plans to in-license additional candidates. Epiphany...
...Phase II to treat disease states associated with water retention. Plans to in-license additional candidates. Epiphany...
Items per page:
1 - 10 of 24
BioCentury | Sep 8, 2014
Analyst Picks & Changes

Analyst picks & changes

...Activating Systems), which Kolbert believes is "best in class." Kolbert said that part of his "epiphany"...
BioCentury | Nov 23, 2009
Clinical News

Valomaciclovir: Phase IIb data

...lesion formation. There were no differences in significant adverse events between treatment groups. Medivir granted Epiphany...
...in 2006 (see BioCentury, Sept 11, 2006). GlaxoSmithKline plc (LSE:GSK; NYSE:GSK, London, U.K.) markets Valtrex. Epiphany Biosciences Inc....
BioCentury | Nov 19, 2009
Clinical News

Epiphany's valomaciclovir meets Phase IIb endpoint

...complete crusting of shingles rash (p<0.007). The double-blind, North American trial (EPB348-0201) enrolled 373 patients. Epiphany...
BioCentury | Apr 9, 2009
Distillery Therapeutics

This week in therapeutics

...for the mutated protein. Valomaciclovir, a varicella zoster DNA polymerase inhibitor from Medivir AB and Epiphany Biosciences Inc....
BioCentury | Mar 5, 2009
Distillery Therapeutics

Indication: Infectious disease

...have vaccines against VZV in early-stage clinical testing. Inhibitex Inc. and partners Medivir AB and Epiphany Biosciences Inc....
BioCentury | Jan 5, 2009
Company News

Epiphany, University of Erlangen-Nuermberg deal

...detect HHV-8. Epiphany expects to launch a diagnostic this year. Financial terms were not disclosed. Epiphany Biosciences Inc....
BioCentury | Sep 22, 2008
Clinical News

Valomaciclovir: Phase IIb ongoing

...vs. 3 times daily Valtrex valacyclovir from GlaxoSmithKline plc (LSE:GSK; GSK, London, U.K.). Medivir granted Epiphany...
...valomaciclovir to treat shingles associated with varicella zoster virus infection (see BioCentury, Sept 6, 2006). Epiphany Biosciences Inc....
BioCentury | Dec 10, 2007
Clinical News

Valomaciclovir: Phase II started

...granted Epiphany worldwide rights outside the Nordic countries to valomaciclovir (see BioCentury, Sept 6, 2006). Epiphany Biosciences Inc....
BioCentury | Nov 12, 2007
Clinical News

Valomaciclovir: Phase IIb started

...once-daily valomaciclovir vs. thrice-daily Valtrex valacyclovir from GlaxoSmithKline plc (LSE:GSK; GSK, London, U.K.). Medivir granted Epiphany...
...valomaciclovir to treat shingles associated with varicella zoster virus infection (see BioCentury, Sept 6, 2006). Epiphany Biosciences Inc....
BioCentury | Sep 3, 2007
Strategy

Back to School 2007: Innovation & leadership

...Phase II to treat disease states associated with water retention. Plans to in-license additional candidates. Epiphany...
...Phase II to treat disease states associated with water retention. Plans to in-license additional candidates. Epiphany...
Items per page:
1 - 10 of 24